QTTB Share Price Performance
US$1.79
-34.04 (-95.00%)
Price US$1.79
Share PriceUS$1.79
QTTB Community Narratives
There are no narratives available yet.
Recent QTTB News & Updates
No updates
Q32 Bio Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -4.29
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -104.2%
Q32 Bio Inc. Competitors
About QTTB
- Founded
- 2017
- Employees
- 29
- CEO
- WebsiteView website
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
U.S. Market Performance
- 7 Days: 0.2%
- 3 Months: 12.2%
- 1 Year: 19.9%
- Year to Date: 7.6%
In the last week, the market has stayed flat, however the Consumer Staples sector stood out, gaining 3.2%. More promisingly, the market is up 20% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading